FUNDING Centre Funding by CINSW $ 5,836, 957 Centre Co-Funding by - - PowerPoint PPT Presentation

FUNDING

80% research infrastructure and direct research support

Centre Funding by CINSW $ 5,836, 957

20% admin (2.6FTE Administration)

Centre Co-Funding by Usyd $ 1,000, 000

• 1. Facilitate the generation of practice improving research and its more rapid adoption

for improved patient outcomes.

• 2. Facilitate evidence into practice research.
• 3. Facilitate the more efficient and effective incorporation of research in:

 Clinical training  Education  Service delivery Within formal governance structure that supports networks and enhanced collaboration

• 4. Build capacity in research and improve competitive advantage in securing other

funds.

CINSW Goals for Translational Cancer Research Centres:

SYDNEY VITAL

Vision: Establish Sydney Vital as a competitive network of excellence in conducting collaborative translational research to improve patient

• utcomes.

Mission: Encourage and promote innovation and collaboration among preclinical and clinical researchers to support cancer research across the translational research pipeline. Business Goal: Making sure the right patient gets the right treatment at the right time as a result of the translational research.

SYDNEY VITAL OBJECTIVES

Self sustainable by 2019. Standardise process to identify right questions that align with health priorities. Build a process to link the right people to do research. Identify process disseminate research findings and support the implementation of evidence into practice in an efficient manner. Develop and maintain essential research infrastructure. Enhance collaborations. Facilitate comprehensive research training and educational programs Leverage funding opportunities and increase competitive advantage Build a supportive governance structure

TRANSLATIONAL RESEARCH IN A NUTSHELL

T2 T1 T3

BASIC SCIENCE TRANSLATIONAL SCIENCE CLINICAL SCIENCE IMPLEMENTATION SCIENCE CLINICAL SERVICES POLICY & PRACTICES

Pillar 1

Flagship 1 Flagship 2 Flagship 3 Flagship 4

Pillar 2 Pillar 3 Pillar 4 Pillar 5

SYDNEY VITAL TRANSLATIONAL Cancer RESEARCH PLAN

5 Pillar initiatives

Capacity Building

9 Research Scholars # Seed Funding

Research Infrastructure

Kolling biobank Pathology research platform SV supports 2.0 FTE Bio-banking Officers SV supports 0.3 FTE research pathologist.

Activity Program Title Program Alignment Supervisor/ Leader Awardees Awarded Amount Period Flagship 1 Investigation of novel insulin-like growth factor (GF)-and sphingosine kinase (sphK)-targeted-therapies for ER-negative, therapy-resistant breast cancer (T1-T2) Pillar 3 Prof Baxter Dr Ochnik $65,000 2014-2015 Flagship 2 Professionalising the Multidisciplinary team Meetings in Neureondocrine

Tumours (T1-T2-T3)

Pillar 1, 2 & 5 Prof Bailey Dr Chan $65,000 2014-2015 Flagship 3 Development and pilot implementation of an evidence-based clinical pathway and toolkit for survivorship care in young women with breast cancer at high risk of stopping endocrine therapy prematurely (T2-T3) Pillar 3 & 4 Prof Boyle Dr Dhillon $65,000 2014-2015 Flagship 4 Nano Medicine in Oncology: improved preoperative staging and better understanding of chemotherapy delivery n (T1-T2-T3) Pillar 1, 2, &3 A/Prof Engel & Prof Dale Bailey 2015-2016 Seed Funding Alllocated to Flagship 4 to support the Nano Medicine project that is being developed A/Prof Engel & Prof Bailey $80,000 Pillar 1 Defining and achieving state of the art cancer diagnosis and treatment Prof Bailey $15,000 2014-2015 Pillar 2 Determining why and when early stage cancer recurs Dr Howell $15,000 2014-2015 Pillar 3 Understanding and overcoming mechanisms of resistance in tumours Prof Marsh $15,000 2014-2015 Pillar 4 Supportive Care, end-Stage Tumours, and end-of-life management Prof Boyle $15,000 2014-2015 Pillar 5 Hereditary Cancer Syndromes A/Prof Gill $15,000 2014-2015 Scholarship Noncoding RNAs as tumour suppressors in adrenal cancer: Unlocking the mechanisms to improve patient outcomes. Prof Sidhu Dr Glover $15,000 2014-2015 Scholarship A Role for p14ARF-p53 in Treatment Resistance and Recurrence in Hormone-dependent Breast Cancer. Dr Nassif Dr Hatoum $15,000 2014-2015 Scholarship The bench-to-bedside clinical implementation of real-time targeted radiotherapy for prostate cancer Prof Keall Dr Colvill $15,000 2014-2015 Scholarship Gene expression profiling of high-grade B-cell lymphomas with NanoString nCounter technology. Validation of a novel diagnostic platform and implementation into clinical use for prognostication and therapeutic decision- making. Prof Stevenson Dr Gifford $15,000 2014-2015 Scholarship Chemotherapeutic prodrugs incorporated within recombinant high density lipoprotein nanoparticles as a modality of targeted delivery. Prof Smith Dr Bulanadi $15,000 2014-2015 Scholarship Currently being assessed TBA TBA $15,000 2014-2015 Scholarship Currently being assessed TBA TBA $15,000 2014-2015 Scholarship Currently being assessed TBA TBA $15,000 2014-2015 Scholarship Currently being assessed TBA TBA $15,000 2014-2015 Total $485,000 2014-2015

SYDNEY VITAL RESEARCH PROGRAMS

Investigation of novel insulin-like growth factor (IGF)-and sphingosine kinase (SphK)-targeted therapies for ER-negative, therapy-resistant breast cancer (T1-T2). Flagship Lead

CIs

Rob Baxter

Stephen Clarke, Debbie Marsh, Fran Boyle, Anthony Gill Mark Molloy

• R. Fellow

Aleksandra Ochnik Flagship 1

Proposal Title: Investigation of novel insulin-like growth factor (IGF)- and sphingosine kinase (SphK)-targeted therapies for ER-negative, therapy-resistant breast cancer.

NETwork (multidisciplinary management of Neureondocrine Tumors (T1-T2-T3). Flagship Lead Dale Bailey CIs Alexander Engel Stephen Clarke Anthony Gill Debbie Marsh

• R. Fellow

David Chan Flagship 2

Project Title: Professionalising the Multidisciplinary team Meetings in Neureondocrine Tumours (T1-T2-T3)

Development and pilot implementation of an evidence-based clinical pathway and toolkit for survivorship care in young women with breast cancer at high risk of stopping endocrine therapy prematurely (T2-T3).

Flagship Lead Fran Boyle CIs Debbie Marsh Stephen Clarke Mark Molloy

• R. Fellow

Haryana Dhillon Flagship 3

Proposal Title: Development and pilot implementation of an evidence-based clinical pathway and toolkit for survivorship care in young women with breast cancer at high risk of stopping endocrine therapy prematurely.

Flagship Lead: Alexander Engel CIs Ewa Goldys Zdenka Kuncic

• R. Fellow

Flagship 4

Nano Medicine in Oncology: improved preoperative staging and better understanding of chemotherapy delivery (T1-T2-T3).

Dale Bailey Robert Knox

Pillar 1 Dale Bailey Anubhav Mittal Christopher Krisp Defining and achieving state of the art cancer diagnosis and treatment. Chief Investor Pillar Leaders

Determining why and when early stage cancer recurs. Pillar 2 Viive Howell Chief Investor Pillar Leaders Helen Wheeler Nham Tran Connie Diakos Kelly Charles

Understanding and overcoming mechanisms of resistance in tumours. Debbie Marsh Helen Wheeler Nham Tran Chief Investor Pillar Leaders

Pillar 3

Connie Diakos Kelly Charles

Supportive care, end-stage tumours, and end-of-life management. Pillar 4 Fran Boyle, Josephine Clayton Melanie Lovell Chief Investor Pillar Leaders April Wong Fred Farzin

Pillar 5 Hereditary Cancer Syndromes. Fred Farzin Chou Dr Crook Michelle Houang Anthony Gill Chief Investor Pillar Leaders

Funding Title CIs Amount Funders Flagship Project Nanostring nCounter system A/Prof Gill A/Prof Engel 250,000 $ PAM Flagship 1&2 Neuroendocrine Tumour Preceptorship A/ProfEngel A/Prof Pavlakis 38,900 $ NOVARTIS Flagship 2 New Paradigms in Rectal Cancer A/Prof Engel Prof Bailey 16,500 $ PETNET Solutions Flagship 2 Educational Support Grant A/Prof Engel Prof Bailey 16,500 $ ANSTO Flagship 2 New Advances Using PET and Radionuclide Therapy A/Prof Engel Prof Bailey 16,500 $ PETNET Solutions Flagship 2 Support salary for Flagship 2 ( FTE 0.4) Dr.Chan 65,000 $ SIRTeX Flagship 2

SYDNEY VITAL LEAVERAGED FUNDS

Funding Title CINSW Scheme CIs Amount Funders Status NanosStreamlining specimen preparation for researchers from samples stored in biobanks,tring nCounter system CINSW Research Equipment Grants Scheme Marsh DJ, Baxter RC, Smith RC, Howell VM, Benn DE, and Engel A 83,797 $ CINSW UNDER MEDIA EMBARGO MS for cancer drug monitoring and biomarker studies CINSW Research Equipment Grants Scheme Molloy M, Baxter RC, Boyages J, Boyle F, Clarke S, Min G, Packer N, Pavlakis N, Anderson M, and Engel A 468,000 $ CINSW UNDER MEDIA EMBARGO Improving quality of life for cancer patietns with Lymphoedema and their carers CINSW Translational Progam Grant Prof Sharon Kilbreath, A/Prof Kerry Sherman, Prof Fran Boyle AM, Prof Dale Bailey, A/Prof Mark Molloy, Ass/Prof Hiroo Suami, and Prof Sheila Ridner Dr Blake Dear, Prof Ewa Goldys 3,750,000 $ CINSW Will be resubmitted the further expansion, maintenance and deployment of a tissue bank of paraffin blocks containing cancers to mirror and expand frozen tissue tumour bank assets”. CINSW Research Infrastructure Grant A/Prof Anthony Gill 228,537 $ CINSW Applied in May 2015 MALDI MS Imaging at Sydney Vital for Cancer Biomarker Discovery CINSW Research Infrastructure Grant Prof Baxter RC xxx CINSW Applied in May 2015

CINSW Fundings

CINSW Grants

Research Infrastructure Grants (RIG) OPENS: March CLOSES: May Career Development Fellowships (CDF) OPENS: February CLOSES: May Early Career Fellowships (ECF) OPENS: February CLOSES: May Research Equipment Grants (REG) OPENS: February CLOSES: April Translational Cancer Research Centre (TCRC) OPENS: March CLOSES: May Translational Cancer Research Centre (TCRC) OPENS: July CLOSES: April Evidence to Practice Grants (ETP) OPENS: February CLOSES: March

Your Ideas?